AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Mar 29, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2005.070300v1
AJPH.2005.070300v2
96/11/1955    most recent
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Nancy S. Green
Siobhan M. Dolan
Thomas H. Murray
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, N. S.
Right arrow Articles by Murray, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, N. S.
Right arrow Articles by Murray, T. H.
©
American Journal of Public Health, 10.2105/AJPH.2005.070300

Analytic Essay Forum

Newborn Screening: Complexities in Universal Genetic Testing

Nancy S. Green 1*, Siobhan M. Dolan 1, Thomas H. Murray 2

1 March of Dimes
2 The HastingsCenter

* To whom correspondence should be addressed. E-mail: ngreen{at}modimes.org.


  Abstract

Newborn screening(NBS)--in which each newborn infant is screened for up to 50 specific metabolic disorders for early detection and intervention--is the first program of populationwide genetic testing. As a public health intervention, NBS has greatly improved the lives of thousands of affected children. New technologies and new economic and social forces pose significant ethical and clinical challenges to NBS. Two primary challenges concern (1) accommodating clinical and ethical standards to rapid technological developments in NBS and (2) preparing public health systems to respond to the medical advances and social forces driving expansion of NBS programs.

We describe and analyze these challenges through consideration of 3 disorders: phenylketonuria, medium-chain acyl-CoA dehydrogenase deficiency, and cystic fibrosis.

Key Words: Ethics, Genetics, Health Policy




This article has been cited by other articles:


Home page
 J Pediatr PsycholHome page
D. B. Bailey Jr, F. D. Armstrong, A. R. Kemper, D. Skinner, and S. F. Warren
Supporting Family Adaptation to Presymptomatic and "Untreatable" Conditions in an Era of Expanded Newborn Screening
J. Pediatr. Psychol., March 30, 2008; (2008) jsn032v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
L. F. Ross
METHODOLOGY MATTERS
Am J Public Health, April 1, 2007; 97(4): 589 - 589.
[Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
N. S. Green and T. H. Murray
GREEN AND MURRAY RESPOND
Am J Public Health, April 1, 2007; 97(4): 589 - 590.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Public Health Association